Beckley Psytech
CEO: Cosmo Fielding-Mellen
Beckley Psytech is developing psychedelic drug programs to develop treatments for various psychiatric conditions, such as treatment-resistant depression, addiction, as well as for a rare disease called SUNHA.
In addition to the long term consequences of current treatment options, innovation has slowed in the area of traditional anti-depressants. Beckley Psytech’s leading compound, 5-MeO-DMT, allows patients to treat their depression and symptoms with promising psychedelic-assisted psychotherapy.
With their decades-long extensive history in research and advocacy, Beckley is well-positioned to introduce psychedelic therapeutics as pharmacological interventions.